ATLANTA – A new collaborative initiative aims to use machine learning to better identify people living with chronic obstructive pulmonary disease who are at risk of exacerbations and hospitalization.
Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and pharmaceutical company GSK to leverage cognitive machine technology and data for patients with COPD.
“The best way to prevent readmission is to prevent admission in the first place,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger. “This initiative will help us identify who is sick enough with COPD to be at risk of admission and how we can prevent it.”
The goal of the initiative is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients currently under the care of Geisinger who are at risk of hospitalization and most likely to benefit from new medications. The CCSM is an advanced artificial intelligence solution built using an Eigen Spheres engine that uses patient mapping to enable a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The initiative, funded by GSK, is divided into two phases: phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This is a huge win for us,” said Craig Kephart, CEO of the COPD Foundation, who said the organization has had multiple requests over the years from health care providers looking for information on best practices to prevent readmissions and exacerbations, and preserve lung function for people with COPD. “Developing these algorithms will help to personalize treatment a little more.”